Motexafin gadolinium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Motexafin gadolinium
Motexafin gadolinium 3D sticks.png
Clinical data
156436-89-4 YesY
PubChem CID 158385
ChemSpider 139341 YesY
KEGG D05080 YesY
ChEBI CHEBI:50161 YesY
Chemical data
Formula C52H72GdN5O14
1148.403 g/mol
 YesY (what is this?)  (verify)

Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1]


On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]

On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]


  1. ^ Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert opinion on pharmacotherapy 8 (3): 351–9. doi:10.1517/14656566.8.3.351. PMID 17266469. 
  2. ^ Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
  3. ^ Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases